Repligen マネジメント
マネジメント 基準チェック /44
Repligenの CEO はOlivier Loeillotで、 Oct2023年に任命され、 の在任期間は 2.58年です。 の年間総報酬は$ 6.11Mで、 14.1%給与と85.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.007%を直接所有しており、その価値は$ 482.31K 。経営陣と取締役会の平均在任期間はそれぞれ2.2年と10.2年です。
主要情報
Olivier Loeillot
最高経営責任者
US$6.1m
報酬総額
| CEO給与比率 | 14.06% |
| CEO在任期間 | 2.6yrs |
| CEOの所有権 | 0.007% |
| 経営陣の平均在職期間 | 2.2yrs |
| 取締役会の平均在任期間 | 10.2yrs |
経営陣の近況
Recent updates
ナラティブ更新 • Apr 25
RGEN: recalibrated Street Expectations Will Shape Bullish Long Term Outlook
The analyst price target for Repligen has been reduced from about $160.90 to $140.00, as analysts factor in updated assumptions for revenue growth, profit margins, discount rates and future P/E following a mix of recent target cuts and one upward revision across the Street. Analyst Commentary Street research on Repligen over recent months points to a mixed but generally more cautious stance, with several firms trimming price targets while one research house lifted its target.
ナラティブ更新 • Apr 09
RGEN: Multi Year Guidance And M&A Dry Powder Will Support Future Upside
Narrative Update on Repligen The analyst price target for Repligen has been adjusted slightly lower, with the updated fair value moving from about $186.82 to $183.88 as analysts factor in recent target cuts, alongside generally positive views on guidance and execution. Analyst Commentary Recent Street research on Repligen clusters around a group of target cuts following the latest Q4 report and FY26 outlook, alongside a smaller number of target increases.Seeking Alpha • Apr 08
Repligen: Advancing, Yet Much More Work Ahead
Summary Repligen has returned to double-digit organic growth, with 2026 guidance for a 10%-14% revenue increase and margin improvement. Despite strong positioning in bioprocessing and a robust net cash balance, Repligen trades at demanding valuations—about 8.5x sales and ~30x 2030 earnings. Management targets 30% EBITDA and 25% EBIT margins by 2030, but current margins remain in the high single-digits to low teens. I remain upbeat on Repligen's growth prospects but cautious on the shares due to high valuation and the need for further margin expansion. Read the full article on Seeking Alphaナラティブ更新 • Mar 25
RGEN: Multi Year Guidance And M&A Focus Will Support Future Upside
Repligen's analyst price target has been adjusted modestly higher to $186.82, with analysts pointing to refreshed assumptions around revenue growth, profit margins, and future P/E expectations following recent target changes across firms such as H.C. Wainwright, UBS, Evercore ISI, Wells Fargo, and Barclays. Analyst Commentary Recent target changes reflect a mix of optimism and caution around Repligen, with analysts adjusting their models after the latest Q4 results and FY26 guidance.ナラティブ更新 • Mar 10
RGEN: M&A And New Bioprocessing Resins Will Support Future Upside
Narrative Update: Repligen Repligen's updated analyst price target reflects a modest reset, with fair value moving from about $190.89 to $186.28 as analysts factor in slightly lower revenue growth and profit margin assumptions along with a marginally higher discount rate, while still generally highlighting solid recent execution and cautious company guidance. Analyst Commentary Recent Street research on Repligen shows a mixed but generally constructive stance, with several firms trimming price targets while maintaining positive ratings.ナラティブ更新 • Feb 24
RGEN: M&A Focus And New Bioprocessing Resins Will Drive Future Upside
Analysts have raised their Repligen price target by $10 to $190.89, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E as reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$190.89 price target as better aligned with updated assumptions for discount rates and future P/E, suggesting the shares may not fully reflect their revised valuation framework.ナラティブ更新 • Feb 09
RGEN: M&A Ambitions And New Resins Portfolio Will Shape Bullish Outlook
Analysts have lifted their price target on Repligen by US$10, citing updated assumptions that reflect revised fair value estimates, a tweaked discount rate, adjusted revenue growth and profit margin expectations, and an updated future P/E multiple. Analyst Commentary Even with the higher price target, some research commentary points to risks that readers should keep in mind when weighing Repligen at current levels.ナラティブ更新 • Jan 26
RGEN: Process Analytics Strength And Biopharma Recovery Will Support Further Upside
Analysts have nudged their price targets on Repligen higher, with our updated fair value estimate moving modestly to about US$190.89 per share. This is supported by recent Street research citing raised targets following a 3Q25 revenue beat and a relatively improving biopharma outlook, with growth across all franchises led by Process Analytics.ナラティブ更新 • Jan 12
RGEN: Process Analytics Strength And Biopharma Recovery Will Support Upside In 2025
Analysts have lifted their price target on Repligen to about US$190 from US$187, pointing to recent target raises, including Canaccord's move to US$165 on 3Q25 revenue outperformance, a relatively improving biopharma outlook, and solid contributions from Process Analytics and other franchises. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a higher price target as a reflection of stronger than expected 3Q25 revenue, which they view as supportive of the current valuation range.ナラティブ更新 • Dec 27
RGEN: Process Analytics Momentum And Biopharma Recovery Will Shape Risk Balanced Outlook
Narrative Update We are raising our Repligen fair value estimate from $131.29 to $160.36 per share as analysts lift price targets toward $160 to $165 on better than expected Q3 results, broad-based revenue growth led by Process Analytics, and an improving outlook for biopharma end markets. Analyst Commentary Recent Street research reflects a cautiously constructive stance on Repligen, with higher price targets acknowledging near term execution outperformance while still embedding meaningful risk around sustainability of growth.
ナラティブ更新 • Dec 13
RGEN: Bioprocessing Recovery And Guidance Raise Will Support Upside Potential
Analysts have nudged our Repligen price target higher to $165, reflecting a modest trim to fair value estimates to about $216.62 per share, alongside slightly lower long term revenue growth and discount rate assumptions, but reinforced by recent target increases from the Street on better than expected quarterly results, improving biopharma demand, and confidence in the company s bioprocessing driven double digit growth potential. Analyst Commentary Bullish analysts have become incrementally more constructive on Repligen following its recent quarterly performance, citing a healthier biopharma demand backdrop and stronger than expected execution across key franchises.ナラティブ更新 • Nov 27
RGEN: Volume Recovery and End-Market Stability Will Support Measured Upside in 2025
Narrative Update on Repligen Analysts have raised their price targets on Repligen by up to $15. They cite stronger-than-expected quarterly results and improved industry outlooks as driving positive momentum for the company.分析記事 • Nov 12
Repligen's (NASDAQ:RGEN) Earnings May Just Be The Starting Point
Even though Repligen Corporation ( NASDAQ:RGEN ) posted strong earnings, investors appeared to be underwhelmed. We did...ナラティブ更新 • Nov 11
RGEN: End-Market Improvements Will Drive Stronger Momentum Through 2025
Analysts have increased their price target for Repligen slightly, from $184.76 to $187.00. They cite a recent revenue beat, an improving sector outlook, and expectations for continued growth across key business areas.分析記事 • Oct 31
Repligen Corporation Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next
Repligen Corporation ( NASDAQ:RGEN ) investors will be delighted, with the company turning in some strong numbers with...ナラティブ更新 • Oct 28
Recovery In Industry Demand And Market Stability Will Drive Renewed Momentum
Repligen's analyst price target has been increased from $179.78 to $184.76, as analysts see improving market stability and anticipate a return to stronger revenue growth despite recent headwinds. Analyst Commentary Recent updates from street research highlight a renewed sense of optimism among analysts, along with acknowledgment of ongoing industry challenges.分析記事 • Oct 04
Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge
Repligen Corporation ( NASDAQ:RGEN ) shares have had a really impressive month, gaining 28% after a shaky period...分析記事 • Sep 01
Is Repligen (NASDAQ:RGEN) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jul 29
Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) P/S
When you see that almost half of the companies in the Life Sciences industry in the United States have price-to-sales...新しいナラティブ • May 26
Biomanufacturing Expansion Will Create New Global Opportunities
Strong demand in biomanufacturing and effective market expansion are driving sustained revenue growth and improved margins for Repligen.Seeking Alpha • Mar 20
Repligen: Ongoing Bioprocessing Market Recovery
Summary I reiterate a 'buy' rating for Repligen with a one-year price target of $175 per share, driven by strong bioprocessing market recovery. Repligen reported 3% organic revenue growth and 13% growth in non-COVID business, with record-high order intakes since Q2 FY22. The acquisition of 908 Devices' bioprocessing analytics portfolio enhances Repligen's process analytical technology, adding significant value to its offerings. Despite challenges in the protein business, I expect 12% organic revenue growth in FY25, supported by new product launches and market normalization. Read the full article on Seeking AlphaSeeking Alpha • Nov 12
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects
Summary Repligen Corporation is a bioprocessing technology company focusing on process intensification, purification, and fluid management, with strategic acquisitions to enhance its capabilities. Though integration risks remain, RGEN's recent acquisition of Tantti Laboratory aims to bolster its chromatography and biomolecule purification capacities. The potential acquisition of Maravai LifeSciences could impact RGEN's future growth, but past failed attempts and divestment plans add uncertainty. Also, I believe international revenue exposure and foreign exchange volatility present additional risks for RGEN’s near-term financial performance. Despite a healthy underlying business, RGEN faces valuation concerns, tax loss harvesting, and uncertain growth, leading to a "Hold" rating ahead of its earnings report. Read the full article on Seeking AlphaSeeking Alpha • Jul 13
Repligen: Strong Filtration Growth, Offset By Other Challenges
Summary Repligen's Q1 revenue declined by 20% organically, driven by Covid-related business decline and reduced demand in China and protein business. Strong growth and pipelines in the core filtration business, with non-Covid filtration revenue surging by more than 15% in Q1. FY24 outlook includes -1% to +4% base revenue growth, with expectations of industry recovery in the second half of 2024 and a one-year price target of $150 per share. Read the full article on Seeking AlphaSeeking Alpha • May 30
Repligen Stock: Still Quite Overvalued
Summary Repligen Corporation stock has dropped 15% since our initial analysis of the stock just over six months ago. The company has posted a couple of quarterly earnings reports since then, and the company's balance sheet is in solid shape. That said, Repligen has hit a growth hiccup, and company insiders have picked up selling shares recently. An updated analysis around Repligen follows in the paragraphs below. Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$51m |
| Dec 31 2025 | US$6m | US$860k | US$49m |
| Sep 30 2025 | n/a | n/a | US$2m |
| Jun 30 2025 | n/a | n/a | -US$14m |
| Mar 31 2025 | n/a | n/a | -US$23m |
| Dec 31 2024 | US$7m | US$650k | -US$26m |
| Sep 30 2024 | n/a | n/a | -US$8m |
| Jun 30 2024 | n/a | n/a | US$9m |
| Mar 31 2024 | n/a | n/a | US$24m |
| Dec 31 2023 | US$5m | US$138k | US$36m |
報酬と市場: Olivierの 総報酬 ($USD 6.11M ) は、 US市場 ($USD 8.41M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Olivierの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Olivier Loeillot (55 yo)
2.6yrs
在職期間
US$6,114,771
報酬
Mr. Olivier Loeillot is President of Repligen Corporation from October 02, 2023 & served as it's Chief Commercial Officer and serves as it's CEO & Director since September 1, 2024. Mr. Loeillot served a co...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 2.6yrs | US$6.11m | 0.0068% $ 482.3k | |
| CFO & Chief Compliance Officer | 2.7yrs | US$2.99m | 0.0069% $ 490.8k | |
| Chief Operating Officer | 6.2yrs | US$2.93m | 0.019% $ 1.3m | |
| Advisor | less than a year | US$671.00k | 0.15% $ 10.4m | |
| Senior Vice President of Research & Development | 9.6yrs | US$2.33m | 0.018% $ 1.3m | |
| Senior VP & Chief Product Officer | 2yrs | US$1.73m | 0.0020% $ 143.3k | |
| Chief Accounting Officer | less than a year | データなし | データなし | |
| Chief Information Officer | 1.3yrs | データなし | データなし | |
| Vice President of Investor Relations | 1.1yrs | データなし | データなし | |
| Senior VP & General Counsel | 1.3yrs | データなし | データなし | |
| Senior Vice President of Sales | 3.6yrs | データなし | データなし | |
| Senior Director of Marketing | 2.3yrs | データなし | データなし |
2.2yrs
平均在職期間
55yo
平均年齢
経験豊富な経営陣: RGENの経営陣は 経験豊富 であると考えられます ( 2.2年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 1.7yrs | US$6.11m | 0.0068% $ 482.3k | |
| Independent Director | 10.6yrs | US$340.28k | 0.063% $ 4.5m | |
| Member of Scientific Advisory Board | 10.2yrs | データなし | データなし | |
| Independent Chair of the Board | 3.3yrs | US$316.28k | 0.011% $ 807.9k | |
| Lead Independent Director | 20.7yrs | US$355.28k | 0.16% $ 11.4m | |
| Independent Director | 2.2yrs | US$318.80k | 0.0019% $ 131.2k | |
| Member of Scientific Advisory Board | 10.2yrs | データなし | データなし | |
| Member of Scientific Advisory Board & Independent Director | 10.2yrs | US$300.28k | 0.0034% $ 241.9k | |
| Member of Scientific Advisory Board | 10.2yrs | データなし | データなし | |
| Independent Director | 6.2yrs | US$305.28k | 0.0054% $ 383.0k | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 11.9yrs | US$311.75k | 0.0062% $ 436.2k |
10.2yrs
平均在職期間
65yo
平均年齢
経験豊富なボード: RGENの 取締役会 は経験豊富で 経験豊富 です ( 10.2年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/07 03:00 |
| 終値 | 2026/05/07 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Repligen Corporation 20 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。29
| アナリスト | 機関 |
|---|---|
| Luke Sergott | Barclays |
| Robert Wasserman | Benchmark Company |
| Hugo Solvet | BNP Paribas |